Study of Patient With Frequent COPD Exacerbations

Who May Qualify: 1. Age ≥ 18 years at the time of inclusion; 2. Signed and dated written willing to sign a consent form in accordance with ICH-GCP and local law prior to inclusion in the study; 3. Patients with diagnosed moderate-to-severe COPD (see comments below); 4. ≥2 moderate or ≥1 severe COPD exacerbations in previous 52 weeks (see comments below); 5. Patients have been receiving two inhaled maintenance therapies (LABA/LAMA, ICS/LABA, ICS/LAMA) for at least 6 weeks prior to inclusion. Who Should NOT Join This Trial: 1. Current or previous treatment with triple combination (ICS/LABA/LAMA) within 52 weeks prior to inclusion; 2. COPD due to documented α-1 antitrypsin deficiency; 3. A diagnosis of bronchiectasis, sarcoidosis, interstitial lung diseases, or idiopathic pulmonary fibrosis, exacerbation of bronchial asthma or any acute or chronic disease that, as deemed by Investigator, limits the ability of patients to participate in this study or could influence the interpretation of the results; 4. The participation in any clinical study currently or within 52 weeks prior to inclusion. Always talk to your doctor about whether this trial is right for you.